AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have earned a consensus recommendation of “Hold” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $19.50.

Several equities research analysts have recently commented on the company. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Finally, HC Wainwright raised their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th.

AngioDynamics Stock Up 1.4%

Shares of AngioDynamics stock opened at $15.49 on Friday. The firm’s 50 day moving average price is $15.27 and its 200-day moving average price is $12.85. AngioDynamics has a 52-week low of $9.39 and a 52-week high of $16.29. The company has a market cap of $640.20 million, a P/E ratio of -17.80 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts forecast that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Activity

In other news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at $953,046.40. The trade was a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 6.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On AngioDynamics

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in AngioDynamics during the second quarter valued at about $49,480,000. Weber Capital Management LLC ADV purchased a new position in shares of AngioDynamics in the 2nd quarter worth about $17,649,392. Paradigm Capital Management Inc. NY acquired a new position in shares of AngioDynamics in the 2nd quarter valued at about $8,732,000. Western Standard LLC acquired a new position in shares of AngioDynamics in the 2nd quarter valued at about $5,037,000. Finally, Bank of America Corp DE grew its holdings in shares of AngioDynamics by 262.7% during the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock worth $5,726,000 after purchasing an additional 364,763 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc (NASDAQ: ANGO) is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company’s product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.